Last quarter (Q1 2024), Iradimed's total revenue was $17.60M, an increase of 13.72% from the same quarter last year. In Q1, Iradimed's net income was $4.14M. See Iradimed’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 67.69M	$ 65.56M	$ 53.30M	$ 41.81M	$ 31.72M	$ 38.52M
Cost of Revenue	$ 11.92M	$ 15.40M	$ 12.02M	$ -9.76M	$ 8.14M	$ 8.82M
Gross Profit	$ 55.77M	$ 50.16M	$ 41.28M	$ 32.05M	$ 23.57M	$ 29.70M
Operating Expense	$ 34.99M	$ 30.12M	$ 25.65M	$ -22.23M	$ 24.33M	$ 21.05M
Operating Income	$ 20.78M	$ 20.04M	$ 15.63M	$ 9.82M	$ -756.09K	$ 8.65M
Net Non Operating Interest Income Expense	$ 1.86M	$ 1.86M	$ 581.85K	$ 18.61K	$ 132.19K	$ 388.80K
Other Income Expense	$ -1.86M	$ -1.70M	$ -553.10K	$ -18.59K	$ 139.21K	$ 7.11K
Pretax Income	$ 22.63M	$ 21.74M	$ 16.18M	$ 9.84M	$ -616.88K	$ 9.04M
Tax Provision	$ 4.71M	$ 4.55M	$ 3.35M	$ 510.82K	$ -1.99M	$ -587.64K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 17.92M	$ 17.19M	$ 12.83M	$ 9.33M	$ 1.37M	$ 9.63M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 46.91M	$ 45.53M	$ 37.68M	$ -32.00M	$ 32.47M	$ 29.87M
Net Income From Continuing And Discontinued Operation	$ 17.92M	$ 17.19M	$ 12.83M	$ 9.33M	$ 1.37M	$ 9.63M
Normalized Income	$ 14.44M	-	-	-	$ 1.37M	$ 9.63M
Interest Expense	-	-	-	-	-	-
EBIT	$ 22.63M	$ 21.74M	$ 16.18M	$ 9.84M	$ -756.09K	$ 8.65M
EBITDA	$ 23.44M	$ 22.50M	$ 16.85M	$ 11.24M	$ 582.73K	$ 9.89M

Currency in USD

Iradimed Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing